Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix

J. A. Levi*, H. R. Wheeler, M. Friedlander, M. H N Tattersall, R. Kefford, D. Dalley

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Forty-three patients with recurrent and metastatic squamous cell carcinoma of the cervix received a program of sequential combination chemotherapy incorporating induction with cisplatin, vinblastine, and bleomycin (PVB) and subsequent consolidation with 5-fluorouracil, doxorubicin, cyclophosphamide, and vincristine (FACV). The overall response rate was 62% and 10 patients (23%) achieved complete remission. Response status was improved in 11 patients at the completion of FACV after initial PVB therapy, including 9 complete remissions. The median survival for all patients in the study was 38 weeks and 50 weeks for the responding patients. Myelosuppression was the principal toxicity encountered and 10 episodes of neutropenic sepsis occurred, including one septic death. However, the only cumulative toxicity was peripheral neuropathy, although this was only moderate to severe in 2 patients. These results are encouraging, but will require confirmation in randomized comparison to cisplatin, presently accepted as standard single-agent therapy.

Original languageEnglish
Pages (from-to)329-333
Number of pages5
JournalGynecologic Oncology
Volume45
Issue number3
DOIs
Publication statusPublished - 1992
Externally publishedYes

Fingerprint Dive into the research topics of 'Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix'. Together they form a unique fingerprint.

Cite this